|1.||Paraneoplastic Cerebellar Degeneration
|3.||Stiff-Person Syndrome (Stiff Man Syndrome)
|1.||Vincent, Angela: 10 articles (02/2015 - 03/2003)|
|2.||Lang, Bethan: 9 articles (02/2015 - 05/2002)|
|3.||Titulaer, Maarten J: 7 articles (07/2013 - 07/2006)|
|4.||Verschuuren, Jan J G M: 6 articles (12/2012 - 07/2005)|
|5.||Wirtz, Paul W: 6 articles (11/2010 - 07/2003)|
|6.||Verschuuren, Jan J: 5 articles (07/2013 - 07/2003)|
|7.||Takamori, Masaharu: 5 articles (12/2012 - 10/2004)|
|8.||Honnorat, J: 5 articles (10/2011 - 01/2000)|
|9.||Motomura, M: 5 articles (07/2009 - 08/2000)|
|10.||Lang, B: 5 articles (03/2004 - 09/2000)|
|1.||Intravenous Immunoglobulins (IVIG)FDA Link
05/01/2005 - "Lambert-Eaton myasthenic syndrome: A placebo-controlled crossover study reported a significant clinical improvement in the amplitude of the resting CMAP following IVIg treatment. "
09/01/2006 - "According to the response to IVIG therapy, paraneoplastic disorders may be subgrouped in group A, a clinical response is the rule (prototype Lambert-Eaton myasthenic syndrome), and in group B, IVIG may be helpful in single patients and is indicated in specific clinical settings (prototype anti-Hu associated neurological syndromes). "
08/01/1996 - "Lambert-Eaton (myasthenic) syndrome: pre-anaesthetic treatment with intravenous immunoglobulins."
03/27/2012 - "IVIg is possibly effective and may be considered for treating nonresponsive dermatomyositis in adults and Lambert-Eaton myasthenic syndrome (Level C). "
10/01/2001 - "In prospective, rigorously controlled, double-blinded clinical trials, IVIg was found to have proven efficacy in the Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, dermatomyositis, and Lambert-Eaton myasthenic syndrome. "
09/01/1998 - "3,4-Diaminopyridine (3,4-DAP) is known to be beneficial in the symptomatic treatment of the Lambert-Eaton myasthenic syndrome (LEMS). "
12/07/1989 - "We conclude that 3,4-diaminopyridine, either alone or in conjunction with other therapies, may be useful in the treatment of Lambert-Eaton myasthenic syndrome."
11/01/2009 - "The purpose of this study was to investigate the clinical and electrophysiological efficacy of 3,4-diaminopyridine (DAP) in patients with Lambert-Eaton myasthenic syndrome (LEMS) in a randomized, double-blind, cross-over drug trial. "
08/01/1998 - "Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome."
01/01/2011 - "Four controlled trials of 3,4-diaminopyridine compared with placebo in a total of 54 participants with Lambert-Eaton myasthenic syndrome were eligible: three cross-over trials and one parallel group. "
01/01/2003 - "A third crossover trial compared intravenous immunoglobulin treatment to placebo in nine patients with Lambert-Eaton myasthenic syndrome. "
12/01/2002 - "Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome."
06/01/1997 - "Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin."
05/01/1997 - "Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin."
02/01/1994 - "[Response to combined therapy with plasmapheresis and high doses of immunoglobulin in Lambert-Eaton syndrome]."
02/01/2015 - "Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels."
07/01/2013 - "Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome."
07/01/2011 - "Lambert-Eaton myasthenic syndrome is caused by antibodies against presynaptic VGCCs. "
07/01/2011 - "Lambert-Eaton myasthenic syndrome (LEMS) is caused by reduced ACh quantal release that occurs mainly because of presynaptic P/Q-type voltage-gated Ca2+ channel (VGCC) antibodies. "
12/01/2010 - "We diagnosed Lambert-Eaton myasthenic syndrome (LEMS) based on the clinical symptoms, the presence of anti-VGCC antibodies and waxing phenomenon on electromyography obtained in April 2009. "
|5.||Guanidine (Guanidine Nitrate)FDA Link
09/01/1997 - "Guanidine hydrochloride is known to be highly effective in the symptomatic treatment of the Lambert-Eaton myasthenic syndrome (LEMS). "
10/01/1977 - "Eaton-Lambert syndrome: reflex improvement with guanidine."
01/14/1978 - "[A further case of Lambert-Eaton syndrome: remarkable action of guanidine]."
04/09/1977 - "Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome."
10/01/1973 - "Guanidine hydrochloride in the Eaton-Lambert syndrome. "
|6.||Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric
10/01/2009 - "Pyridostigmine seems not to have an additional effect to 3-4 diaminopyridine in Lambert Eaton myasthenic syndrome. "
07/01/2007 - "[Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine]."
09/01/1997 - "Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome."
07/01/2009 - "Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study."
07/01/2009 - "3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination. "
|7.||Calcium Channels (Calcium Channel)IBA
04/01/2013 - "[Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome]."
12/01/2012 - "Lambert-Eaton myasthenic syndrome (LEMS) causes neuromuscular weakness as a result of an autoimmune attack on the calcium channels that normally regulate chemical transmitter release at the neuromuscular junction. "
07/01/2009 - "Serum anti-P/Q-voltage-gated calcium channel antibody was positive, confirming the diagnosis of Lambert-Eaton myasthenic syndrome (LEMS). "
01/01/2009 - "Lambert-Eaton myasthenic syndrome is a disorder of neuromuscular transmission in which an autoantibody is directed against the pre-synaptic calcium channel. "
06/15/2008 - "Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome."
01/01/1997 - "Some disorders, such as the Lambert-Eaton myasthenic syndrome, are effectively treated by removal of autoantibodies directed against the presynaptic cholinergic synapse. "
09/01/2003 - "Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome."
04/01/1999 - "wt 58,000) are general targets of Lambert-Eaton myasthenic syndrome autoantibodies. "
05/13/1998 - "The role of autoantibodies in Lambert-Eaton myasthenic syndrome."
01/01/1995 - "The autoantibodies implicated in the Lambert-Eaton myasthenic syndrome (LES), which are known to inhibit ICa and INa in bovine adrenal chromaffin cells, also significantly inhibited INa in SCLC cells. "
|9.||Immunoglobulin M (IgM)IBA
05/01/1997 - "In other controlled or open-label trials and case reports, IVIg produced improvement in several patients with the Lambert-Eaton myasthenic syndrome and myasthenia gravis but had a variable, mild, or unsubstantiated benefit in some patients with inclusion-body myositis, paraproteinemic IgM demyelinating polyneuropathy, certain intractable childhood epilepsies, polymyositis, multiple sclerosis, optic neuritis, and the stiff-man syndrome. "
05/01/1995 - "The neurological diseases with definite or putative immune pathogenesis include myasthenia gravis; Lambert-Eaton myasthenic syndrome; IgM monoclonal anti-myelin-associated glycoprotein-associated demyelinating polyneuropathy; Guillain-Barré syndrome; chronic inflammatory demyelinating polyneuropathy; multifocal motor neuropathy with or without GM1 antibodies; multiple sclerosis; inflammatory myopathies; stiff-man syndrome; autoimmune neuromyotonia; paraneoplastic neuronopathies and cerebellar degeneration; and neurological diseases associated with systemic autoimmune conditions, vasculitis, or viral infections. "
04/01/2007 - "Recommendations for use of IVIG were made for 14 conditions, including acute disseminated encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, diabetic neuropathy, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathy, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, polymyositis, Rasmussen's encephalitis, and stiff person syndrome; IVIG was not recommended for 8 conditions including adrenoleukodystrophy, amyotropic lateral sclerosis, autism, critical illness polyneuropathy, inclusion body, myositis, intractable childhood epilepsy, paraproteinemic neuropathy (IgM variant), and POEMS syndrome. "
11/01/1994 - "These are; ple21 in limbic encephalitis; PCD17, CDR62, CDR34, and CZF in paraneoplastic cerebellar degeneration; one of the anion transporters band 3 in chorea-acanthocytosis; visinin-like substance in cancer-associated retinopathy (CAR syndrome); myelin basic protein (MBP) and proteolipid protein (PLP) in acute disseminated encephalomyelitis; MBP, PLP and myelin-oligodendrocyte glycoprotein (MOG) in multiple sclerosis; glutamic acid decarboxylase in stiff-man syndrome; GM1 ganglioside in amyotrophic lateral sclerosis; peripheral nerve K+ channel in Isaacs syndrome; synaptotagmin in Lambert-Eaton syndrome; acetylcholine receptor in myasthenia gravis; GM1 ganglioside in Guillain-Barré syndrome; GQ1b ganglioside in Fisher syndrome; myelin-associated glycoprotein in IgM paraproteinemic neuropathy; HuD in paraneoplastic sensory neuropathy; and tRNA and HSP65 in polymyositis."
|10.||Immunoglobulin G (IgG)IBA
02/10/2015 - "Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels."
04/01/1999 - "The immunoglobulin G fractions from Lambert-Eaton myasthenic syndrome patients immunoprecipitate solubilized neuronal N- and P/Q-type channels and in certain cases brain, skeletal and cardiac muscle L-type channels [El Far O. "
11/01/1996 - "Incubation of cells with Lambert-Eaton myasthenic syndrome IgG for 24 to 48 hours removed up to 71% of the whole-cell current. "
08/15/1995 - "1. The effects of immunoglobulin G (IgG) from patients with Lambert-Eaton myasthenic syndrome on Ca2+ currents in mammalian motor nerve terminals are unknown. "
03/03/1995 - "The immunochemical and functional properties of IgG fractions from patients with Lambert-Eaton myasthenic syndrome (LEMS) were examined in chick and rat synaptosomes. "
|1.||Drug Therapy (Chemotherapy)
07/01/2006 - "Chemotherapy has successfully ameliorated the course of disease in Lambert-Eaton myasthenic syndrome patients with an underlying tumour."
03/01/1994 - "Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy."
01/01/1979 - "Eaton-Lambert syndrome: electrophysiological normalization during chemotherapy."
06/01/1982 - "Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome."
01/01/1982 - "To our knowledge, it has not been reported before that chemotherapy alone of a small cell bronchogenic carcinoma has resulted in clinical, roentgenologic, and electrophysiologic remission of the Eaton-Lambert syndrome."
04/01/1984 - "Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome."
08/01/1981 - "The myasthenic (Eaton-Lambert) syndrome, associated with carcinoma of the bronchus in one patient and with immunological disorders in two others, improved after plasma exchange--observations supported by electromyographic evidence in two cases. "
07/01/2006 - "Although widely used, the potential benefit of plasma exchange in the treatment of multiple sclerosis, myasthenia gravis, and Lambert-Eaton syndrome is less clear."
08/01/1984 - "Treatment with plasma exchange, steroids, immunosuppressant drugs and cytotoxic chemotherapy was effective in two cases of cancer-associated Eaton-Lambert myasthenic syndrome. "
04/01/1984 - "We undertook serial clinical and electromyographic muscle action potential (MAP) amplitude assessments in nine patients with the Lambert-Eaton myasthenic syndrome (LEMS) over 0.5 to 2.5 years who received plasma exchange (PE; 5 to 15 exchanges over 4 to 19 days) and immunosuppressive drug (IS) treatment (prednisolone 60 to 100 mg on alternate days, azathioprine 2.5 mg/kg for 0.5 to 2.5 years), and who had no signs of carcinoma at entry. "
10/01/2014 - "Knowledge about the dosing, adverse effects, and costs of immunomodulatory therapies is essential for the effective management of patients with MG and Lambert-Eaton myasthenic syndrome."
01/01/2014 - "The nine nonparaneoplastic Lambert-Eaton myasthenic syndrome patients responded to immunomodulatory therapy with close return to their baseline function. "
08/01/1997 - "Treatment of the tumour and/or immunomodulation did not alter the course of paraneoplastic cerebellar degeneration, but improved Lambert-Eaton myasthenic syndrome symptoms. "
08/01/2013 - "[Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome]."
08/01/2013 - "We report a 41-year-old man who presented with a seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome in whom conventional immunosuppressive treatments (corticosteroids, azathioprine) failed, and who eventually improved after treatment with rituximab. "